To investigate the effect of TREK–1 in the experimental tissue fibrosis model, the classical bleomycin model of pulmonary fibrosis was employed, and the TREK–1 inhibitor fluoxetine (FLX) was used. This evidence concerns the gene KCNK2 and pulmonary fibrosis.